Clinical Trial Update: Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

View source ↗

Summary

This is a completed special drug-use surveillance study of 300 mg intravenous vedolizumab for ulcerative colitis, with results posted on 2025-09-11.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Entyvio (vedolizumab)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Ulcerative Colitis | Status: COMPLETED | Results posted: 2025-09-11